- Events, Presentations and Webcasts
- Repros in the News
- Analyst Coverage
- SEC Filings
- Corporate Governance
Repros Therapeutics Inc.
$4.53 (-0.01)
January 2012 - Current
February 2012
Repros Announces the Closing of a Registered Direct Offering of Approximately $11.1 Million
February 2, 2012
January 2012
Repros Announces Registered Direct Offering of Approximately $11.1 Million
January 27, 2012
Repros to Present at Bioshowcase in San Francisco on 1/9/12 and Host Analyst Day in New York on 1/25/12
January 5, 2012
Repros' IND for Proellex®-V Accepted by the FDA
January 4, 2012
Repros Completes Dosing in Phase 2 Low-Dose Oral Proellex® Trial
January 3, 2012
Donald Tredway MD, PhD, Joins Repros As Chief Medical Officer
January 3, 2012
October 2011 - December 2011
December 2011
Repros Receives Official FDA Minutes from Type C Meeting Held on 12/13/11 Confirming Path Forward for Androxal®
December 27, 2011
Men Entering One Year Extension Study of ZA-203 Elect Treatment with Androxal® Over Approved Topical Testosterone Product
December 27, 2011
Top-Line Phase 2B Data Indicate Androxal® Raises Testosterone Equivalent to Testim Without Impairing Spermatogenisis
December 22, 2011
November 2011
Oral Androxal® Achieves Equivalent 24 Hour Average Testosterone Levels Compared to Leading FDA Approved Testosterone Gel
November 7, 2011
July 2011 - September 2011
September 2011
Repros Commences Dosing of Last Cohort in Oral Proellex® Low Dose Study
September 20, 2011
Repros to Submit IND for Vaginal Delivery of Proellex® for Fibroid De-bulking and Symptom Elimination
September 8, 2011
Interim Data from Low Dose Oral Proellex® Study Supports Repros’ Belief of a Return to Phase III in 2012
September 7, 2011
August 2011
Repros Therapeutics Inc.® Reports Second Quarter 2011 Financial Results
August 9, 2011
April 2011 - June 2011
June 2011
Repros Therapeutics® Enrolls Fourth Cohort in Low Dose Proellex® Study
June 23, 2011
May 2011
Repros Therapeutics Inc.® Reports First Quarter 2011 Financial Results
May 16, 2011
Repros Therapeutics® Provides Clinical Update for Androxal® Study in Men with Type 2 Diabetes
May 2, 2011
January 2011 - March 2011
March 2011
Repros Therapeutics® Commences Dosing Third Cohort in Low Dose Proellex® Study
March 16, 2011
Repros Reports Results from Completed 1 MG Dose Cohort in Low Dose Proellex® Study
March 15, 2011
Repros Announces Dismissal of Class Action Lawsuits
March 3, 2011
February 2011
Repros Therapeutics® Announces Pricing of Public Offering of Common Stock and Warrants
February 3, 2011
January 2011
Repros Therapeutics® Receives IRB Approval to Commence Phase IIb Study of Androxal® in the Treatment of Secondary Hypogonadism
January 3, 2011
October 2010 - December 2010
December 2010
Vaginal Delivery of Repros'® Proellex® Bypasses First Pass Liver Effects and Achieves Greater Signals of Efficacy at Significantly Lower Exposure
December 27, 2010
Repros® Therapeutics Prepares to Commence Dosing in Second Cohort in Low Dose Proellex® Study
December 16, 2010
November 2010
Repros Therapeutics Inc.® Reports Third Quarter 2010 Financial Results and Provides Corporate Update
November 10, 2010
Repros® Therapeutics Reports Outcome of Type B Meeting with FDA Regarding Androxal® in the Treatment of Secondary Hypogonadism
November 9, 2010
October 2010
Repros® Has Regained Compliance with NASDAQ Continued Listing Requirements
October 29, 2010
Repros® Therapeutics Begins Randomization of Subjects in Androxal® Type II Diabetes Phase II Trial
October 25, 2010
Repros® Announces Reverse Stock Split Effective On NASDAQ on October 15, 2010
October 14, 2010
July 2010 - September 2010
September 2010
FDA Grants Type B Meeting to be Held November 8, 2010 to Discuss Phase III Protocols for Androxal®
September 30, 2010
Repros® Announces Board Approval of Reverse Stock Split
September 29, 2010
August 2010
REPROS REQUESTS TYPE B MEETING WITH FDA TO DISCUSS PHASE III PROTOCOLS FOR ANDROXAL®
August 18, 2010
NASDAQ GRANTS REPROS EXTENSION UNTIL OCTOBER 31, 2010 TO MEET MINIMUM BID PRICE LISTING REQUIREMENT
August 13, 2010
REPROS THERAPEUTICS GRANTED KEY PATENT FOR ANDROXAL®
August 11, 2010
Repros Therapeutics Inc. Reports Second Quarter 2010 Financial Results
August 9, 2010
REPROS THERAPEUTICS SUSPENDS AT-THE-MARKET OFFERING OF COMPANY SECURITIES
August 3, 2010
July 2010
REPROS THERAPEUTICS RECEIVES INVESTIGATIONAL REVIEW BOARD APPROVAL TO COMMENCE LOW DOSE FOR PROELLEX® STUDY AT ICON SITE
July 22, 2010
April 2010 - June 2010
June 2010
NASDAQ SETS JULY 22, 2010 FOR REPROS HEARING TO APPEAL NASDAQ DELISTING NOTICE
June 17, 2010
REPROS TO APPEAL NASDAQ DELISTING NOTICE
June 16, 2010
FDA LIFTS FULL CLINICAL HOLD ON REPROS' PROELLEX®
June 11, 2010
May 2010
Repros Therapeutics Inc. Reports Outcome of Annual Meeting Shareholder Vote
May 17, 2010
Repros Therapeutics Inc. Reports First Quarter 2010 Financial Results
May 10, 2010
April 2010
REPROS RECEIVES GUIDANCE FROM FDA REGARDING CLINICAL HOLD STATUS OF PROELLEX®
April 30, 2010
REPROS ANNOUNCES COMPLIANCE WITH NASDAQ MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT
April 15, 2010
REPROS REQUESTS LIFT OF CLINICAL HOLD ON PROELLEX®
April 5, 2010
January 2010 - March 2010
March 2010
FDA'S METABOLIC DIVISION DEEMS REPROS PHASE II PROTOCOL ADEQUATE FOR EXPLORING THE EFFECTS OF ANDROXAL® ON BLOOD GLUCOSE
March 31, 2010
Repros Therapeutics Inc. Reports Fourth Quarter And Year End 2009 Financial Results
March 15, 2010
REPROS RECEIVES OFFICIAL FDA MINUTES FROM TYPE C ANDROXAL® MEETING
March 3, 2010
February 2010
REPROS ESTABLISHES AT-THE-MARKET PUBLIC STOCK OFFERING PROGRAM
February 18, 2010
REPROS SUBMITS RESPONSE TO FDA REGARDING ANDROXAL® INDICATION FOR TREATMENT OF HYPOGONADAL MEN WISHING TO PRESERVE FERTILITY
February 8, 2010
January 2010
REPROS RECEIVES GUIDANCE FROM FDA REGARDING CONTINUED DEVELOPMENT OF ANDROXAL® IN HYPOGONADAL MEN
January 27, 2010
REPROS APPROVED FOR TRADING ON NASDAQ CAPITAL MARKET
January 15, 2010
REPROS SHELF REGISTRATIONS OF STOCK ARE EFFECTIVE
January 11, 2010
October 2009 - December 2009
December 2009
REPROS AWAITS NASDAQ RULING REGARDING DELISTING APPEAL
December 21, 2009
November 2009
REPROS APPOINTS DR. JAYE THOMPSON TO BOARD OF DIRECTORS
November 12, 2009
REPROS TO APPEAL NASDAQ DELISTING NOTICE
November 9, 2009
Repros Therapeutics Inc. Reports Third Quarter 2009 Financial Results
November 9, 2009
October 2009
Repros Therapeutics Announces Settlement with Major Creditors
October 30, 2009
Repros Therapeutics Announces Amendment of NIH Proellex® License
October 28, 2009
Repros Therapeutics Inc. Announces Financing
October 8, 2009
REPROS REPORTS ANDROXAL® RESTORES NORMAL SPERM COUNTS WHILE INCREASING TESTOSTERONE LEVELS IN HYPOGONADAL MEN
October 6, 2009
August 2009 - September 2009
September 2009
Repros Therapeutics Inc. Provides Update on Proellex®
September 29, 2009
Repros Therapeutics Inc. Receives Additional NASDAQ Delisting Notice
September 21, 2009
Repros Therapeutics Inc. Announces Financing
September 8, 2009
August 2009
Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update
August 17, 2009
Repros Therapeutics Inc. Announces That United States Food and Drug Administration Places Proellex® On Clinical Hold
August 6, 2009